[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"small-lymphocytic-lymphoma-sll\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:small-lymphocytic-lymphoma-sll":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,78,109,135,163,183,210,240,264],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100594842","phase-2-phase-2-study-of-disease-risk-mutation-guided-finite-acalabrutinibvenetoclax-for-relapsed-cll-post-1l-finite-cbtkibcl2i--obinutuzumab-100594842",false,"NCT07024706","Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","The MAVRiC Study: A Phase II Study of Disease Risk Mutation Guided Finite Duration Acalabrutinib Plus Venetoclax for Relapse in CLL\u002FSLL After First-line Finite Covalent BTKi Plus BCL2i Combination, With or Without Obinutuzumab","MAVRiC","Main Inclusion Criteria:\n\n1. Participant must be ≥ 18 years at the time of signing informed consent.\n2. Diagnosis of CLL\u002FSLL according to iwCLL guidelines 2018 (Hallek et al. 2018)\n3. Participants must have received first line treatment with fixed duration covalent BTKi plus BCL2i therapy (± obinutuzumab) with a response ≥ PR (i.e., CR, CRi, nPR, or PR) with a minimum of 2 years since the end of the prior 1L treatment.\n4. The following data must be available or at least the appropriate samples drawn\u002Facquired prior to dosing:\n\n   1. IGHV (mutated vs. unmutated)\n   2. del(17p) (present or absent)\n   3. TP53 mutation (present or absent)\n5. ECOG performance status 0, 1 or 2\n6. Adequate organ and bone marrow (BM) function.\n\nMain Exclusion Criteria:\n\n1. Any evidence of diseases that, in the investigator's opinion, makes it undesirable for patient to participate in the study.\n2. Significant cardiovascular or cerebrovascular disease.\n3. Active bleeding or history of bleeding diathesis (e.g., hemophilia or von Willebrand disease).\n4. Child-Pugh B\u002FC liver cirrhosis.\n5. History of prior or current malignancy.\n6. HIV positive\n7. History of progressive multifocal leukoencephalopathy (PML).\n8. Active hepatitis B or C infection:\n9. Corticosteroid use \\> 20 mg within 1 week before the first dose of study intervention.\n10. History of hypersensitivity or anaphylaxis to study intervention(s).\n11. Requires treatment with a strong CYP3A4 inhibitor\u002Finducer.\n12. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists.\n13. Major surgical procedure within 30 days of the first dose of study intervention.","ALL","18 Years","130 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.",[28,29],"Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)",[28,29,31,32,33],"Relapsed CLL","Refractory CLL","Acalabrutinib","RECRUITING","2026-07-01",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":38},"2026-06-04",{"date":42,"type":22},"2033-03-23",{"name":44,"class":45},"AstraZeneca","INDUSTRY",36,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100609970","phase-2-a-study-of-nx-5948-in-adults-with-cllsll-previously-treated-with-a-brutons-tyrosine-kinase-inhibitor-and-a-b-cell-lymphoma-2-inhibitor-daybreak-cll-201-100609970","NCT07221500","A Study of NX-5948 in Adults With CLL\u002FSLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)","A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed\u002FRefractory (R\u002FR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)","Inclusion Criteria:\n\n* Age: ≥ 18 years\n* Confirmed relapsed\u002Frefractory CLL\u002FSLL that meets iwCLL criteria for diagnosis and systemic treatment\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Must have received a covalent BTK inhibitor (BTKi), a non-covalent BTKi, and a BCL-2 inhibitor either in separate lines of therapy or in combination; a line of therapy is considered 2 or more consecutive cycles of a systemic anti-CLL\u002FSLL regimen\n* Participants with SLL must have measurable disease by radiographic assessment\n* Adequate organ and bone marrow function\n* Must sign an informed consent form indicating that he or she understands the purpose of the procedures required for the study and is willing to participate\n\nExclusion Criteria:\n\n* Known or suspected prolymphocytic leukemia or Richter's transformation before entering study\n* Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) before planned start of study drug\n\n  * Antibody therapy must stop at least 4 weeks before the first dose of study drug\n  * No other systemic anticancer therapy is allowed at the same time as this study; exception: continuation of hormonal therapy for breast and prostate cancer is allowed, if they are not on the list of prohibited concomitant medications in this study\n* Palliative limited-field radiotherapy within 7 days of the first dose of study or broad field radiotherapy within 28 days of first dose of study drug\n* Use of systemic corticosteroids \\>20 mg\u002Fday prednisone or equivalent within the 7 days before start of study drug except for those used as premedication for radio diagnostic contrast\n* Use of systemic immunosuppressive drugs other than systemic corticosteroids within 60 days before the first dose of study drug\n* Previously treated with a BTK degrader\n* Previous chimeric antigen receptor (CAR) T-cell therapy or allogeneic or autologous hematopoietic cell transplant within the past 90 days prior to enrollment\n* Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), stroke, or intracranial hemorrhage within 6 months of planned start of study drug\n\nNote: Other Inclusion\u002FExclusion criteria may apply as defined in the protocol.",{"count":55,"type":22},100,[25],"This is a study for patients with relapsed\u002Frefractory (R\u002FR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL\u002FSLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.",[28,29],[60,61,62,63,64,65,66,67,68,28,29],"BTK Degrader","BTK Inhibitor","BCL-2 Inhibitor","B-cell Malignancy","Lymphoma","Bruton's Tyrosine Kinase","NX-5948","Targeted Protein Degradation","Chimeric Targeting Molecule (CTM)","2026-06-30",{"date":37,"type":38},{"date":72,"type":38},"2025-10-15",{"date":74,"type":22},"2030-10",{"name":76,"class":45},"Nurix Therapeutics, Inc.",32,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":89,"conditions":90,"keywords":98,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100449326","phase-1-a-study-of-nx-5948-in-adults-with-relapsedrefractory-b-cell-malignancies-100449326","NCT05131022","A Study of NX-5948 in Adults With Relapsed\u002FRefractory B-cell Malignancies","A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed\u002FRefractory B-cell Malignancies","Key Inclusion Criteria:\n\n* Age ≥18 years\n* Patients in Phase 1a (Dose Escalation) must have histologically confirmed R\u002FR CLL, SLL, DLBCL (subgroups include Richter-transformed DLBCL, germinal center B-cell type, activated B-cell type, high-grade B-cell lymphoma with MYC and BCL-2 and\u002For BCL-6 rearrangements, high-grade B-cell lymphomas NOS), FL, MCL, MZL (subtypes include EMZL, MALT, NMZL, SMZL), WM, or PCNSL.\n* Patients in Phase 1a must meet the following:\n\n  o For non-PCNSL indications, received at least 2 prior lines of therapy and have no other available therapies known to provide clinical benefit. For PCNSL, received at least 1 prior line of therapy\n* Patients in Phase 1b (Safety and Cohort Expansion) must have 1 of the following histologically documented B-cell malignancies, must meet criteria for systemic treatment, and must have received prior therapies and\u002For molecular features based on details described for each cohort: CLL or SLL, DLBCL, MCL, FL, MZL, WM, or PCNSL\u002FSCNSL.\n* Measurable disease per response criteria specific to the malignancy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (0-2 for patients with PCNSL and secondary CNS involvement).\n* Adequate organ and bone marrow function\n\nKey Exclusion Criteria:\n\n* Known or suspected active prolymphocytic leukemia or Richter's transformation to Hodgkin's lymphoma prior to study enrollment\n* Prior treatment for the indication under study for anti-cancer intent that includes:\n\n  1. Radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation).\n  2. Prior systemic chemotherapy within 2 weeks of planned start of study drug.\n  3. Prior monoclonal antibody therapy within 4 weeks of planned start of study drug, except for patients enrolling in Cohort 16 (CLL with secondary wAIHA) where a 16-week washout period is required.\n  4. Prior small molecule therapy within 2 weeks or 5 half-lives (whichever is shorter) of planned start of study drug.\n  5. Autologous or allogeneic stem cell transplant within 100 days prior to planned start of study drug.\n  6. Chimeric antigen receptor (CAR) T-cell therapy within 100 days prior to start of study drug (within 60 days prior to start of study drug for Phase 1b).\n  7. Use of systemic corticosteroids outside of dosing limits described below and within 7 days prior to initiation of study treatment excepting those used as prophylaxis for radio diagnostic contrast. Patients with PCNSL\u002FSCNSL: no greater than 40 mg\u002Fday prednisone, or equivalent. Patients with PCNSL\u002FSCNSL using greater than 20 mg\u002Fday prednisone, or equivalent, must be clinically stable at that dose for 7 days. All other diagnoses: no greater than 20 mg\u002Fday prednisone or equivalent.\n  8. Use of systemic immunosuppressive drugs other than systemic corticosteroids for any medical condition within 60 days prior to first dose of study drug\n  9. Previously treated with a BTK degrader\n* Active, uncontrolled autoimmune hemolytic anemia (except for patients enrolling in Cohort 16) or active, uncontrolled autoimmune thrombocytopenia.\n* Patient has any of the following within 6 months of planned start of study drug:\n\n  1. Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, or placement of a coronary arterial stent\n  2. Uncontrolled atrial fibrillation or other clinically significant arrhythmias, conduction abnormalities, or New York Heart Association (NYHA) class III or IV heart failure\n  3. Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), stroke, or intracranial hemorrhage\n  4. Any other significant cardiac condition (e.g., pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, severe congenital heart disease, or persistent uncontrolled hypertension defined as systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg despite optimal medical management)\n* Bleeding diathesis, or other known risk for acute blood loss.\n* History of Grade ≥ 2 hemorrhage within 28 days of planned start of study drug.\n* Active known concurrent malignancy or malignancy other than the one under study within the past 3 years. (Exceptions include, but are not limited to, patients with more recent history of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast may enroll if they have undergone curative therapy and have no evidence of disease).",{"count":86,"type":22},572,[88],"PHASE1","This is a first-in-human Phase 1a\u002F1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.",[28,29,91,92,93,94,95,96,97],"Diffuse Large B Cell Lymphoma (DLBCL)","Follicular Lymphoma (FL)","Mantle Cell Lymphoma (MCL)","Marginal Zone Lymphoma (MZL)","Waldenstrom Macroglobulinemia (WM)","Primary Central Nervous System Lymphoma (PCNSL)","Secondary Central Nervous System Lymphoma (SCNSL)",[60,61,99,64,100,101,65,66,67,68],"B-Cell Malignancy","C481","C481S",{"date":37,"type":38},{"date":104,"type":38},"2022-04-13",{"date":106,"type":22},"2028-01",{"name":76,"class":45},62,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":134},"100625905","early-phase-1-immune-profiling-of-cllsll-treated-with-first-line-pirtobrutinib-100625905","NCT07428707","Immune Profiling of CLL\u002FSLL Treated With First-Line Pirtobrutinib","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures\n2. Age \\>=18 years\n3. Confirmed diagnosis of CLL or SLL according to International Workshop on CLL (iwCLL) guidelines\n\n   1. Coexpression of CD5, CD19, CD20, and CD23 expression and light-chain restriction; CD23 dim or negative expression is acceptable as long as other parameters are consistent with a diagnosis of CLL.\n   2. CLL: clonal B-lymphocytosis \\>=5,000 cells\u002FmL\n\n   OR\n\n   SLL: lymphadenopathy with the tissue morphology of CLL but that are not leukemic, \\\u003C5,000 cells\u002FmL\n4. Active disease requiring treatment according to iwCLL guidelines\n5. Measurable disease characterized by \\>=1 of the following:\n\n   1. Lymphadenopathy: \\>=1 lymph node measuring \\>=1.5 cm in the greatest diameter\n   2. Splenomegaly: spleen measuring \\>13 cm in craniocaudal length\n   3. Lymphocytosis: \\>=5,000 B cells\u002FmicroL\n   4. Bone marrow infiltration: CLL comprising \\>= 30% of all cells\n6. Previously untreated CLL with \\>=1 LN amenable to core-needle biopsy\n7. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n8. The patient has adequate organ function for all of the following criteria, as defined below:\n\n   * System: Hepatic\n\n     * Laboratory Value: ALT or AST: \\\u003C= 3 x the ULN or \\\u003C= 5 x ULN with documented liver involvement\n     * Laboratory Value: Total bilirubin: \\\u003C= 1.5 x ULN or \\\u003C= 3 x ULN with documented liver involvement and\u002For Gilbert s Disease\n   * System: Renal\n\n     --Laboratory Value: Serum creatinine: Calculated creatinine clearance \\>= 30 ml\u002Fmin according to Cockcroft\u002FGault Formula: \\[(140-age) x body weight (kg) x 0.85 (if female)\\]\u002F \\[serum creatinine (mg\u002FdL) x 72\\]\n   * System: Hematologic\n\n     * Laboratory Value: Hemoglobin: \\>= 8 g\u002FdL (\\>= 80 g\u002FL)\n     * Laboratory Value: ANC: \\>= 0.75 x 10\\^9\u002FL\n     * Laboratory Value: Platelets: \\>= 50 x 10\\^9\u002FL\n\n   Notes:\n\n   Hgb and platelets: independent of transfusions within 7 days of Screening assessment.\n\n   ANC: independent of growth factor support within 7 days of Screening assessment.\n\n   Criteria must be met on C1D1 without transfusion\u002FG-CSF within 7 days of assessment.\n\n   Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST =aspartate aminotransferase; ULN = upper limit of normal.\n9. Adequate coagulations, defined as activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and prothrombin (PT) or international normalized ratio (INR) not greater than 1.5 X ULN.\n10. Willingness of WOCBP and their partners to observe highly effective birth control methods for the duration of treatment and for 1 month following the last dose of study treatment.\n11. Ability to take oral medication and be willing to adhere to the study drug regimen\n12. Agreement to adhere to Lifestyle Considerations throughout study duration\n13. Able to understand and willing to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n1. Diagnosis of Richter Transformation\n2. Documented CNS involvement\n3. Pregnancy or plan to become pregnant during the study or within 1 month of the last dose of study treatment. WOCBP must have a negative serum pregnancy test.\n4. Lactation or plan to breastfeed during the study or within 1 week of the last dose of study treatment.\n5. Known active cytomegalovirus (CMV) infections. Unknown or negative status are eligible.\n6. Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection based on criteria below:\n\n   1. Patients with positive hepatitis B surface antigen (HBsAg) are excluded.\n   2. Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require a negative hepatitis B polymerase chain reaction (PCR) evaluation before randomization.\n   3. Patients who are HBV DNA PCR positive will be excluded.\n7. Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before randomization. Patients who are hepatitis C RNA positive will be excluded.\n8. Patients who have tested positive for Human Immunodeficiency Virus (HIV) and have a detectable viral load and\u002For a CD4 count \\\u003C350 are excluded due to risk of opportunistic infections with both HIV and BTK inhibitors. Eligible patients with HIV must be stable on antiretroviral therapy \\>=4 weeks prior to study entry. For patients with unknown HIV status, HIV testing will be performed at Screening and result must be negative for enrollment.\n9. Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drug. (e.g., gastric bypass surgery, gastrectomy).\n10. Evidence of other clinically significant uncontrolled condition(s) including but not limited to, uncontrolled systemic bacterial, viral, fungal or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the investigator and medical monitor may pose a risk for patient participation. Screening for chronic conditions is not required.\n11. Stroke or intracranial hemorrhage within 6 months of screening\n12. Hypertensive urgency or emergency\n13. Active, clinically significant cardiovascular disease including:\n\n    * Unstable angina or acute coronary syndrome within the past 2 months prior to screening\n    * Documentation of LVEF by any method of \\\u003C= 40% in the 12 months prior to screening\n    * Uncontrolled or symptomatic arrhythmias\n    * Class 3 or 4 congestive heart failure as defined by New York Heart Association Functional Classification\n    * Myocardial infarction, unstable angina or acute coronary syndrome within 3 months of screening.\n    * Prolongation of the QT interval corrected for heart rate (QTcF) \\> 470 msec. QTcF is calculated using Fridericia s Formula (QTcF): QTcF=QT\u002F(RR\\^0.33)\n\n    Correction of suspected drug-induced QTcF prolongation can be attempted at the investigator s discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation.\n\n    \\- Correction for underlying bundle branch block (BBB) allowed.\n\n    Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker\n14. Known allergy\u002Fsensitivity to pirtobrutinib or any of the excipients (hydroxypropyl methylcellulose acetate succinate, microcrystalline cellulose, mannitol, sodium starch glycolate, and magnesium stearate.).\n15. History of bleeding diathesis (e.g. von Willebrand disease or hemophlia)\n16. Has received a live vaccine or live-attenuated vaccine within 28 days before the first dose of pirtobrutinib. Administration of killed vaccines are allowed.\n17. Patients requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist are excluded. Direct oral anticoagulants (DOACs) are allowed.\n18. Diagnosis of primary immunodeficiency or is receiving chronic systemic steroid therapy (in dosing \\>20 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication.\n19. Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid)\n20. Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia \\[AIHA\\], idiopathic thrombocytopenic purpura \\[ITP\\]) for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts.\n21. Active second malignancy unless in remission and with life expectancy \\>2 years.\n\n    Note: Participants are eligible if they have prostate cancer under active surveillance or observation.\n22. Has not adequately recovered after 4 weeks from major surgery or has ongoing surgical complications.\n23. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n24. Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant s participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.","100 Years",{"count":117,"type":22},30,[119],"EARLY_PHASE1","Background:\n\nChronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. Pirtobrutinib is a drug approved to treat CLL and SLL after 2 previous treatments. Researchers want to know how this drug affects the immune system in those who have not yet started other treatments for CLL or SLL.\n\nObjective:\n\nTo test pirtobrutinib as a first-line treatment for CLL or SLL.\n\nEligibility:\n\nPeople aged 18 years and older with untreated CLL or SLL.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood tests. They will have imaging scans and tests of their heart function. They will have a lymph node biopsy: A large needle will be inserted into a lymph node to collect a small piece of tissue.\n\nPirtobrutinib is a tablet taken by mouth. Participants will take 2 to 4 tablets daily in 4-week cycles.\n\nParticipants will have clinic visits once every 4 weeks for the first 3 months. Then they will be seen once every 3 months.\n\nImaging scans, lymph node biopsy, and other tests will be repeated at various study visits.\n\nA bone marrow biopsy (collection of soft tissue from inside a bone) may be done if there is no evidence of disease after 1 year of treatment with the study drug.\n\nParticipants may opt to have cancer and immune cells collected from their blood. The cells will be used for research.\n\nParticipants will have a clinic visit 1 month after their last dose of the study drug. Then they will have follow-up visits or phone calls every 6 to 12 months....",[28,29],[123,28,124],"Pirtobrutinib","Immune profiling","2026-06-03",{"date":40,"type":38},{"date":128,"type":38},"2026-03-11",{"date":130,"type":22},"2030-03-01",{"name":132,"class":133},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":159,"locationsCount":162},"100581392","phase-2-zanubrutinib-obinutuzumab-and-sonrotoclax-in-previously-untreated-patients-with-cll-or-sll-100581392","NCT06849713","Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL","A Phase 2 Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","BOSon","Inclusion Criteria:\n\n* Participant must have CLL or SLL (WHO criteria).\n* Participant must require treatment according to iwCLL guidelines.\n* Participants must have no prior systemic therapy for CLL or SLL, except:\n\n  * Prior local radiation for symptomatic disease is permitted.\n  * Short course systemic corticosteroids is permissible for disease control, improvement of performance status, or non-cancer indication. However, duration of steroid course must be ≤14 days with maximum daily dose of ≤100 mg prednisone, ≤20 mg dexamethasone, or equivalent, and must be discontinued prior to study treatment (last dose may be administered up until the morning of \u002F prior to study treatment). Inhaled steroids, topical steroids, and replacement \u002F stress corticosteroids are permitted independent of above rules. In cases of autoimmune complications of CLL (e.g., ITP or AIHA), steroid usage is permitted.\n* Age ≥18 years.\n* ECOG performance status of 0, 1 or 2.\n* Participants must meet the following organ and marrow function as defined below:\n\n  * absolute neutrophil count ≥1,000\u002FµL without growth factor support (filgrastim within 5 days or PEGfilgrastim within 10 days of test), unless clearly due to disease under study (per investigator)\n  * platelets ≥75,000\u002FµL, or ≥20,000\u002FµL if clearly due to disease under study (per investigator)\n  * total bilirubin ≤2 x institutional upper limit of normal (ULN), or ≤3 x institutional ULN if due to Gilbert's syndrome, or with PI approval if clearly due to disease under study\n  * AST(SGOT)\u002FALT(SGPT) ≤2.5 x × institutional ULN\n  * CrCl or GFR ≥30 mL\u002Fmin as estimated by the Cockcroft-Gault equation, the CKD-EPI equation, or as measured by 24-hour urine collection\n* For females of childbearing potential, a serum pregnancy test must be negative within screening period.\n* For female patients of childbearing potential: agreement to use highly effective form(s) of contraception (i.e., one that results in a low failure rate \\[\\\u003C1% per year\\] when used consistently and correctly) or remain abstinent (refrain from heterosexual intercourse) during the treatment period and to continue its use for ≥ 30 days after the last dose of zanubrutinib or ≥ 90 days after the last dose of sonrotoclax, and for ≥18 months fter the last dose of obinutuzumab (whicher is later).\n\n  * A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (\\>12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and\u002For uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). The definition of childbearing potential may be adapted for alignment with local guidelines or regulations.\n  * Examples of contraceptive methods with a failure rate of \\\u003C 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Hormonal contraceptive methods must be supplemented by a barrier method.\n  * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n* For men with a female partner of childbearing potential or a pregnant female partner: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom in addition to 1 of the highly effective methods of contraception listed below, from the time of taking the first dose of study drug , during the treatment period and to continue its use for ≥ 30 days after the last dose of zanubrutinib or ≥ 90 days after the last dose of sonrotoclax, and for ≥18 months fter the last dose of obinutuzumab (whicher is later).\n\n  --The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n* Willingness to not donate or bank sperm or oocytes during the entire study treatment period and after treatment discontinuation for for ≥ 30 days after the last dose of zanubrutinib or ≥ 90 days after the last dose of sonrotoclax, and for ≥18 months fter the last dose of obinutuzumab (whicher is later).\n* Ability to understand and the willingness to sign a written informed consent document. (Providing consents in as many languages as possible is encouraged)\n\nExclusion Criteria:\n\n* Known histologic transformation from CLL or SLL to an aggressive lymphoma (i.e., Richter's transformation).\n* Known central nervous system involvement with CLL or SLL.\n* Other diagnosis of active malignancy or systemic therapy within 2 years of study treatment. Note: An active malignancy or systemic therapy within 2 years for another malignancy, whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Also, local\u002Fregional therapy with curative intent such as surgical resection or localized radiation at any timepoint is permitted.\n* Any uncontrolled illness that in the opinion of the investigator would preclude administration of study therapy (e.g., significant active infections, hypertension, angina, arrhythmias, pulmonary disease, or autoimmune dysfunction).\n* Congestive heart failure, New York Heart Association III\u002FIV. Unstable angina within 3 months before screening, myocardial infarction within 6 months before screening. History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes). Heart rate-corrected QT interval \\> 480 milliseconds based on Fridericia's formula corrected for bundle branch block as appropriate. History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place.\n* Receipt of a live-virus vaccine within 28 days prior to initiation of study treatment or need for live-virus vaccine at any time during study treatment.\n* Active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds).\n* Known bleeding diathesis. History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention.\n* Prior major surgical procedure within 4 weeks of study, or anticipation of need for a major surgical procedure during the course of the study.\n* Known CNS hemorrhage or stroke within 6 months of the study.\n* History of progressive multifocal leukoencephalopathy.\n* History of HIV infection or active hepatitis B (chronic or acute) or hepatitis C infection.\n\n  * Patients with a history of HIV infection that is well controlled on antiretroviral therapy are eligible if all of the following criteria are met: (1) undetectable HIV viral load by standard clinical assay AND (2) CD4+ T cell count of \\>\u002F=200 cells\u002Fmicroliter). NOTE: Many HIV regimens are excluded based on drug interactions, and concomitant antiretroviral therapy must be acceptable per protocol.\n  * Participants with occult or prior HBV infection (defined as positive total hepatitis B core antibody \\[HBcAb\\] and negative HBsAg) may be included if HBV DNA is undetectable, and if the participant is willing to take appropriate anti-viral prophylaxis as indicated and HBV DNA monitoring on study.\n  * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.\n\nKnown condition or other clinical situation resulting in inability to swallow oral medications, or that would impair absorption of oral medications.\n\n* Participant in a separate investigational therapeutic trial unless authorized by the PI.\n* Concurrent therapy with, or administration within 5 half-lives 14 days prior to the first dose of study drug (whichever is shorter), with moderate or strong inhibitors or inducers of CYP3A.\n* Concomitant use of warfarin or warfarin derivatives.\n* Concomitant use of dual antiplatelet therapy.\n* Prior systemic therapy for CLL or SLL, except for localized radiation or corticosteroids as per 3.1.3.\n* Prior anti-CD20 monoclonal antibody therapy for any indication (malignant or non-malignant).\n* Participants with a contraindication to obinutuzumab based on known hypersensitivity (IgE-mediated) reaction to obinutuzumab or to any of its excipients. Hypersensitivity to zanubrutinib or sonrotoclax.\n* Consumption of one or more of the following within 3 days prior to the first dose of study drug: grapefruit or grapefruit products, Seville oranges including marmalade containing Seville oranges, or Star fruit (carambola).\n* Known psychiatric illness or social situation that would interfere with study adherence.\n* Pregnant women are excluded from this study given potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued prior to the first dose of study drug if the mother is treated.\n* Uncontrolled autoimmune anemia and\u002For autoimmune thrombocytopenia (eg, idiopathic thrombocytopenia purpura), e.g., with need for ongoing corticosteroid treatment (see 3.2.24).\n* Requires ongoing need for corticosteroid treatment. NOTE: Systemic corticosteroids must be fully tapered off\u002Fstopped before first study drug.\n* Uncontrolled hypertension at Screening, defined as systolic blood pressure \\> 170 mmHg and diastolic blood pressure \\> 105 mmHg by ≥ 2 consecutive measurements. In patients NOT meeting these parameters for uncontrolled hypertension, repeat blood pressure measurement is NOT required for eligibility.",{"count":144,"type":22},40,[25],"The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).",[148,29],"Chronic Lymphocytic Leukemia",[150,151,152],"CLL","SLL","untreated","2026-05-15",{"date":155,"type":38},"2026-05-19",{"date":157,"type":38},"2025-05-16",{"date":130,"type":22},{"name":160,"class":161},"Massachusetts General Hospital","OTHER",2,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":134},"100595280","predictors-of-health-related-qol-in-adults-with-cll-or-small-lymphocytic-lymphoma-100595280","NCT07030400","Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma","Predictors of Health-Related Quality of Life in Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Inclusion Criteria:\n\n* All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +\u002F- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included.\n* Subjects must be able to read and speak English or Spanish at the 8th grade level.\n\nExclusion Criteria:\n\n* Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.",{"count":55,"type":22},"OBSERVATIONAL","The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.",[29,28],"2026-03-31",{"date":176,"type":38},"2026-04-01",{"date":178,"type":38},"2025-07-17",{"date":180,"type":22},"2028-06",{"name":182,"class":161},"H. Lee Moffitt Cancer Center and Research Institute",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":209},"100426218","phase-1-a-study-of-nx-2127-in-adults-with-relapsedrefractory-b-cell-malignancies-100426218","NCT04830137","A Study of NX-2127 in Adults With Relapsed\u002FRefractory B-cell Malignancies","A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed\u002FRefractory B-cell Malignancies","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age\n* Patients must have measurable disease per disease-specific response criteria\n* Patients with indolent forms of NHL must meet the criteria requiring systemic treatment (i.e., iwCLL, IWG, Lugano Classification of Lymphoma response criteria, or International PCNSL Collaborative Group response criteria)\n* Patients with transformed lymphoma are eligible for the study with the exception of those detailed in Exclusion Criteria #1: Prolymphocytic leukemia, MCL with blastoid histology, MCL with pleomorphic morphology, or MCL with known TP53 mutation\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (non-PCNSL indications) or 0 - 2 (PCNSL patients)\n* Adequate organ and bone marrow function\n* Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol\n\nInclusion Criteria for Patients in Phase 1a:\n\n* Have histologically confirmed R\u002FR CLL, SLL, WM, MCL, and MZL, FL, DLBCL, or PCNSL\n* Received at least 2 prior systemic therapies (or at least 1 prior therapy for patients with WM or PCNSL) and have no other therapies known to provide clinical benefit\n* Must require systemic therapy\n\nInclusion Criteria for Patients in Phase 1b:\n\n* Must have one of the following histologically documented R\u002FR B-cell malignancies:\n\n  * CLL\u002FSLL whose disease has failed treatment with a BTKi;\n  * MCL whose disease has failed treatment with BTKi and an anti-CD20 mAb-based regimen\n  * FL or MZL whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTKi\n  * PCNSL whose disease failed at least 1 prior line of treatment\n  * DLBCL whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen, or another\u002F palliative regimen (either progressed post stem cell transplant or transplant-ineligible)\n\nExclusion Criteria:\n\n* Active, uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia\n* History of known\u002Fsuspected other autoimmune disease (exception(s): patients with alopecia, vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at screening are allowed.)\n* Unable to swallow capsules or have a condition that may interfere in the delivery, absorption, or metabolism of the study drug\n* Bleeding diathesis, or other known risk for acute blood loss\n* Patients requiring ongoing treatment with warfarin or an equivalent vitamin K antagonist and within 7 days prior to the first dose of study drug\n* Prior radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation)\n* Toxicities from previous anticancer therapies must have resolved to baseline levels or to Grade 1 (except for alopecia, hypothyroidism with adequate replacement therapy, hypopituitarism with adequate replacement therapy, peripheral neuropathy or hematologic parameters meeting inclusion criteria).\n* Active known second malignancy. Exception: patients with non-metastatic, non-melanoma skin cancer are eligible\n* Patient has had major surgery (e.g. requiring general anesthesia) within 4 weeks before the planned first dose of study drug\n* Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: patients with well-controlled HIV (e.g., CD4 \\> 350\u002Fmm3 and undetectable viral load) are eligible.\n* Current active liver disease from any cause\n* Active viral reactivation (e.g., CMV or EBV)\n* Use of systemic corticosteroids exceeding 20 mg\u002Fday prednisone (or equivalent) for non-PCNSL indications within 15 days prior to the planned start of study drug. PCNSL patients may not exceed corticosteroid doses of 40 mg\u002Fday prednisone (or equivalent) and should be on a stable or decreasing dose for 7 days prior to planned study start.\n* Use of non-steroidal immunosuppressive drugs within 30 days prior to start of the study\n* Clinically significant, uncontrolled cardiac, cardiovascular disease, or history of myocardial infarction within 6 months of planned start of study drug\n* Administration of any strong cytochrome P450 3A (CYP3A) inducers or inhibitors for 14 days prior to the first dose of study drug, and any P-glycoprotein inhibitors (for 2 days) or moderate inducers of CYP3A for 7 days",{"count":191,"type":22},248,[88],"This is a first-in-human Phase 1a\u002F1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.",[28,29,95,93,94,92,195,96],"Diffuse Large B-cell Lymphoma (DLBCL)",[60,61,63,64,197,198,199,65,200,67,68,100,101],"IMiD","Lenalidomide","Pomalidomide","NX-2127","2026-03-18",{"date":203,"type":38},"2026-03-20",{"date":205,"type":38},"2021-05-05",{"date":207,"type":22},"2027-05",{"name":76,"class":45},16,{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":222,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":239},"100283222","phase-2-a-study-of-venetoclax-in-participants-with-relapsed-or-refractory-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-100283222","NCT02966756","A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Inclusion Criteria:\n\n* Participant must have a diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL) that meets 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (iwCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines and the following:\n\n  * Participant must have an indication for treatment according to the 2008 Modified iwCLL NCI-WG Guidelines.\n  * SLL participant must have measurable disease (B-lymphocytosis greater than 5 × 10\\^9\u002FL or an enlarged lymph node(s) (Longest Diameter (LDi) \\> 1.5 cm at baseline) or hepatomegaly or splenomegaly due to CLL).\n  * SLL participant must have presence of lymphadenopathy and absence of cytopenias caused by a clonal marrow infiltrate.\n  * Participant must have relapsed or refractory CLL\u002FSLL after receiving at least one prior line of therapy.\n* Participants (in Cohort 1) must have 17p deletion, assessed by a central laboratory.\n* Participants (in Cohort 2) must meet both of the following:\n\n  * Relapsed\u002Frefractory disease to B-Cell Receptor Signaling Pathway Inhibitor (BCRI) treatment;\n  * And either of the following: (a) relapsed\u002Frefractory disease to chemoimmunotherapy (CIT), or (b) ineligible to receive CIT, defined as having known 17p deletion or TP53 mutation, or Cumulative Illness Rating Scale (CIRS) \\>6 or calculated creatinine clearance \\\u003C70 mL\u002Fmin, or participants in whom the investigator evaluated that the use of CIT was inappropriate.\n* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2.\n* Participant must have adequate bone marrow function, coagulation profile, renal, and hepatic function, per laboratory reference range at Screening.\n* No known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\n\nExclusion Criteria:\n\n* Participant has undergone an allogeneic stem cell transplant.\n* Participant has developed Richter's transformation confirmed by biopsy.\n* Participant has prolymphocytic leukemia.\n* Participant has active and uncontrolled autoimmune cytopenias (for 2 weeks prior to screening), including autoimmune hemolytic anemia (AIHA) and idiopathic thrombocytopenic purpura (ITP).\n* Participant has previously received venetoclax or other BCL-2 inhibitors.\n* Participant is known to be positive for Human Immunodeficiency Virus (HIV).\n* Participant has received a biologic agent for anti-neoplastic intent within 30 days prior to the first dose of study drug.\n* Participant has received any of the following within 14 days or 5 half-lives (whichever is shorter) prior to the first dose of venetoclax, or has not recovered to less than Common Toxicity Criteria for Adverse Events (CTCAE) grade 2 clinically significant adverse effect(s)\u002Ftoxicity(s) of the previous therapy:\n\n  * Any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy or targeted small molecule agents.\n  * Investigational therapy, including targeted small molecule agents.\n* Participant has known allergy to both xanthine oxidase inhibitors and rasburicase.",{"count":218,"type":22},110,[25],"This is a Phase 2, open-label, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL) either in presence of 17p deletion (Cohort 1) or those who have failed a B-receptor signaling pathway inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status (Cohort 2).",[28,29],[223,224,225,226,227,228,29,229],"Relapsed chronic lymphocytic leukemia (CLL)","Refractory chronic lymphocytic leukemia (CLL)","17p deletion","Venetoclax","Leukemia","Lymphoproliferative Disorders","Venclexta","2025-12-18",{"date":232,"type":38},"2025-12-24",{"date":234,"type":38},"2017-10-12",{"date":236,"type":22},"2029-05",{"name":238,"class":45},"AbbVie",31,{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":263},"100452240","phase-2-zanubrutinib-and-venetoclax-in-cll-zanu-ven-100452240","NCT05168930","Zanubrutinib and Venetoclax in CLL (ZANU-VEN)","A Phase 2 Trial of Zanubrutinib and Venetoclax in Previously Treated CLL\u002FSLL Patients","Inclusion Criteria\n\n* Confirmed diagnosis of CLL or SLL as per 2018 International Workshop on CLL (IWCLL) criteria.\n* Participants must have relapsed after at least one prior line of therapy and must currently require therapy by 2019 IWCLL criteria.\n* For enrollment to Cohort A: Participants must be covalent BTK and BCL-2 inhibitor naïve. Participants who have received prior therapy with a covalent BTK or BCL-2 inhibitor are not eligible, including but not limited to prior treatment with ibrutinib or acalabrutinib.\n* For enrollment to Cohort B: Participants must have had prior treatment with a BTK inhibitor or a BCL-2 inhibitor, but not both, and must not have experienced disease progression as defined by iwCLL criteria while receiving therapy.\n* For enrollment to Cohort C: participants must have a disease that progressed during therapy with a covalent BTK inhibitor, not including zanubrutinib.\n* Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of zanubrutinib and venetoclax in participants \\\u003C 18 years of age and CLL\u002FSLL is extremely rare in this population, children are excluded from this study.\n* ECOG performance status ≤ 2 (Karnofsky ≥ 60%, see Appendix A).\n* Participants must have adequate organ function as defined below:\n\n  * Platelet count ≥ 20,000\u002FmcL\n  * Total bilirubin ≤ 2 × institutional upper limit of normal (ULN) (unless due to controlled hemolysis, Gilbert's disease, or is of non-hepatic origin)\n  * AST (SGOT) and ALT (SGPT) ≤ 4 × institutional ULN\n  * Serum Creatinine ≤ 1.5 × institutional ULN, OR\n  * Calculated creatinine clearance ≥ 50 mL\u002Fmin (as calculated by the Cockcroft-Gault formula)\n* The effects of zanubrutinib or venetoclax on the developing human fetus are unknown. For this reason and because anti-cancer agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study agent administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n* Ability to swallow and retain oral medication.\n\nExclusion Criteria:\n\n* Known BTK C481X mutation.\n* For enrollment to Cohort B: participants who have received prior treatment with both a BTK inhibitor and BCL-2 inhibitor.\n* Participants who have had previous anti-cancer therapy (e.g., chemotherapy, radiotherapy, immunotherapy, biologic therapy, hormonal therapy, surgery, investigational agents, and\u002For tumor embolization) within 2 weeks of Cycle 1 Day 1 with the following exceptions:\n* Hormonal therapy given in the adjuvant setting\n* Corticosteroid therapy (prednisone or equivalent ≤ 20 mg daily) is allowed as clinically warranted as long as the dose is stabilized at least for 7 days prior to initial dosing. Topical, inhaled, intra-articular, or ophthalmologic corticosteroids are permitted\n* Participants enrolling to Cohort C may remain on prior BTK inhibitor therapy up until 2 days prior to Cycle 1 Day 1\n* History of a prior allogeneic hematologic stem cell transplant.\n* Participants with known central nervous system (CNS) involvement, because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Participants with no known history of CNS involvement are not required to undergo CT scan or lumbar puncture (LP) for trial eligibility unless the participant is symptomatic as judged by the treating investigator.\n* Participants who are receiving any other investigational agents at the time of study entry.\n* History of other malignancies, with the following exceptions:\n\n  * Malignancy treated with curative intent and with no known active disease present for ≥ 2 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n  * Adequately treated carcinoma in situ without evidence of disease\n  * Low-risk prostate cancer on active surveillance\n* Participants who have been vaccinated with live, attenuated vaccines \\\u003C 4 weeks prior to Cycle 1 Day 1.\n* Recent infection requiring intravenous antibiotics completed ≤ 7 days before the first dose of study drug, or any uncontrolled active systemic infection.\n* Known bleeding disorders (e.g. von Willebrand's disease) or hemophilia.\n* History of stroke, intracranial hemorrhage, or recent major bleed within 6 months prior to study entry.\n* Participants who require warfarin or other vitamin K antagonists for anticoagulation (other anticoagulants are allowed with approval from the overall principal investigator).\n* Participants who are known at the time of study entry to require concomitant treatment with any medications or substances that are moderate or strong CYP3A inhibitors or inducers. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment\u002Finformed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.\n* Known history of human immunodeficiency virus (HIV), active hepatitis C virus (HCV), or hepatitis B virus (HBV).\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to zanubrutinib or venetoclax.\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because zanubrutinib and venetoclax are anti-cancer agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with zanubrutinib or venetoclax, breastfeeding should be discontinued if the mother is treated with zanubrutinib or venetoclax.\n* Participants with malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.\n* Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to study entry.\n* Any life-threatening illness, medical condition, or organ system dysfunction that, in the treating investigator's opinion, could compromise the participant's safety or the integrity of the trial.\n* Active and\u002For ongoing autoimmune anemia and\u002For autoimmune thrombocytopenia.",{"count":248,"type":22},45,[25],"This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).",[28,29],[253,226],"Zanubrutinib","2025-12-01",{"date":256,"type":38},"2025-12-05",{"date":258,"type":38},"2022-02-18",{"date":260,"type":22},"2028-10-28",{"name":262,"class":161},"Dana-Farber Cancer Institute",4,{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":134},"100576695","a-study-of-patients-with-relapsedrefractory-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-treated-with-lisocabtagene-maraleucel-in-the-post-marketing-setting-100576695","NCT06788639","A Study of Patients With Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting","Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma in the Post-Marketing Setting","Inclusion Criteria:\n\n• Participants must have been treated in the post-marketing setting with ≥1 infusion of lisocabtagene maraleucel used for the treatment of relapsed\u002Frefractory (R\u002FR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) within the approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA\n\nExclusion Criteria:\n\n* Participants known to be participating in investigational studies at the time of lisocabtagene maraleucel infusion\n* Patients treated with non-conforming CAR T-cell product",{"count":272,"type":22},300,"The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities",[28,29],[28,29],"2025-02-21",{"date":278,"type":38},"2025-02-24",{"date":280,"type":38},"2025-02-04",{"date":282,"type":22},"2044-06-30",{"name":284,"class":45},"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company"]